Pregnancy outcome following first trimester exposure to sumatriptan

被引：56

作者：

Shuhaiber, S

Pastuszak, A

Schick, B

Matsui, D

Spivey, G

Brochu, J

Koren, G

机构：

[1] Hosp Sick Children, Div Clin Pharmacol & Toxicol, Motherisk Program, Dept Pediat, Toronto, ON M5G 1X8, Canada

[2] Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada

[3] Univ Toronto, Toronto, ON, Canada

[4] Penn Healthline, Philadelphia, PA USA

[5] Childrens Hosp Western Ontario, Fetal Risk Assessment Program, London, ON, Canada

[6] Univ Connecticut, Ctr Hlth, Div Human Genet, Connecticut Pregnancy Exposure Informat Serv, Farmington, CT USA

来源：

NEUROLOGY | 1998年 / 51卷 / 02期

关键词：

D O I：

10.1212/WNL.51.2.581

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

We prospectively compared pregnancy outcome after exposure to sumatriptan with that of disease-matched controls and nonteratogen controls. There were no differences in the rates of live births, spontaneous abortions, therapeutic abortions, or major birth defects among the three groups. This first prospective report suggests that the use of sumatriptan during organogenesis is not associated with an apparent increased risk of major birth defects.

引用

页码：581 / 583

页数：3

共 6 条

[1] MIGRAINE SYNDROME IN PREGNANCY [J].

CALLAGHAN, N .

NEUROLOGY, 1968, 18 (02) :197-+

[2] THE CLINICAL-PHARMACOLOGY, PHARMACOKINETICS AND METABOLISM OF SUMATRIPTAN [J].

FOWLER, PA ;

LACEY, LF ;

THOMAS, M ;

KEENE, ON ;

TANNER, RJN ;

BABER, NS .

EUROPEAN NEUROLOGY, 1991, 31 (05) :291-294

[3]

Heinonen O, 1977, BIRTH DEFECTS DRUGS

[4] HEADACHES AND WOMEN - TREATMENT OF THE PREGNANT AND LACTATING MIGRAINEUR [J].

SILBERSTEIN, SD .

HEADACHE, 1993, 33 (10) :533-540

[5] MIGRAINE AND PREGNANCY [J].

UKNIS, A ;

SILBERSTEIN, SD .

HEADACHE, 1991, 31 (06) :372-374

[6]

WELCH KMA, 1993, NEW ENGL J MED, V329, P1476

← 1 →